Karabinos A - Search Results

1

Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.

Fleck C, Karabinos A, Cook A, Moore DC, Jacobs R. Fleck C, et al. Among authors: karabinos a. Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38646879 No abstract available.

2

Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.

Hamadeh IS, Moore DC, Martin A, Karabinos A, Hill H, Ndiaye A, Robinson JD, Paul BA, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Hamadeh IS, et al. Among authors: karabinos a. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):470-475. doi: 10.1016/j.clml.2021.02.014. Epub 2021 Mar 4. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33785299

3

Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.

Moore DC, Granger K, Hill H, Karabinos A, Davis JA. Moore DC, et al. Among authors: karabinos a. Expert Rev Hematol. 2024 May 11:1-4. doi: 10.1080/17474086.2024.2353751. Online ahead of print. Expert Rev Hematol. 2024. PMID: 38717927 No abstract available.

4

Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.

Chojecki AL, Arnall J, Boselli D, Patel R, Chiad Z, DiSogra KY, Karabinos A, Chen T, Cruz A, Verbyla A, Ai J, Knight TG, Ragon BK, Shah NA, Sanikommu SR, Symanowski J, Avalos BR, Copelan EA, Grunwald MR. Chojecki AL, et al. Among authors: karabinos a. Leuk Res. 2022 Aug;119:106904. doi: 10.1016/j.leukres.2022.106904. Epub 2022 Jun 21. Leuk Res. 2022. PMID: 35753088 No abstract available.

5

Visualization of the composition of the urinary fluorescent metabolome. Why is it important to consider initial urine concentration?

Dubayová K, Birková A, Lešo M, Žilková J, Karabinoš A, Mareková M, Stupák M. Dubayová K, et al. Among authors: karabinos a. Methods Appl Fluoresc. 2023 Jul 19;11(4). doi: 10.1088/2050-6120/ace512. Methods Appl Fluoresc. 2023. PMID: 37414001

6

The long protostomic-type cytoplasmic intermediate filament (cIF) protein in Branchiostoma supports the phylogenetic transition between the protostomic- and the chordate-type cIFs.

Karabinos A. Karabinos A. Protoplasma. 2023 Nov;260(6):1493-1500. doi: 10.1007/s00709-023-01865-3. Epub 2023 May 20. Protoplasma. 2023. PMID: 37209173

7

Dilated cardiomyopathy is a part of the ARV1-associated phenotype: a case report.

Karabinos A, Hyblova M, Eckertova M, Tomkova E, Schwartzova D, Luckanicova N, Magyarova G, Minarik G. Karabinos A, et al. J Med Case Rep. 2022 Feb 28;16(1):98. doi: 10.1186/s13256-022-03291-0. J Med Case Rep. 2022. PMID: 35227294 Free PMC article.

8

Promiscuous Dimerization Between the Caenorhabditis elegans IF Proteins and a Hypothesis to Explain How Multiple IFs Persist Over Evolutionary Time.

Karabinos A, Schünemann J, Parry DAD. Karabinos A, et al. J Mol Evol. 2019 Sep;87(7-8):221-230. doi: 10.1007/s00239-019-09904-5. Epub 2019 Aug 12. J Mol Evol. 2019. PMID: 31407015

9

Analysis of the novel excretory cell expressed ECP-1 protein and its proposed ECP-1/IFC-2 fusion protein EXC-2 in the nematode Caenorhabditis elegans.

Karabinos A, Schulze E, Baumeister R. Karabinos A, et al. Gene Expr Patterns. 2019 Dec;34:119061. doi: 10.1016/j.gep.2019.119061. Epub 2019 Jun 15. Gene Expr Patterns. 2019. PMID: 31207388

10

Intermediate filament (IF) proteins IFA-1 and IFB-1 represent a basic heteropolymeric IF cytoskeleton of nematodes: A molecular phylogeny of nematode IFs.

Karabinos A. Karabinos A. Gene. 2019 Apr 15;692:44-53. doi: 10.1016/j.gene.2018.12.069. Epub 2019 Jan 12. Gene. 2019. PMID: 30641223

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page